지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2016.1
- 수록면
- 219 - 224 (6page)
이용수
초록· 키워드
오류제보하기
The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/ F/TDF) were analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naïve and ART-experienced Asian subjects infected with human immunodeficiency virus (HIV)-1. Studies GS-US-236-102 and GS-US-236-103 were randomized, double-blind, placebo-controlled, 144-week studies conducted in ART-naïve subjects, comparing E/C/F/TDF versus efavirenz (EFV)/F/TDF or ritonavir-boosted atazanavir (ATV+RTV) plus emtricitabine/tenofovir DF (F/TDF), respectively. Studies GS-US-236-115 and GSUS- 236-121 were randomized, open-label, 96-week long conducted in ART-experienced subjects, who switched to E/C/F/TDF from ritonavir-boosted protease inhibitors (PI+RTV)+F/TDF, or non-nucleoside reverse transcriptase inhibitors (NNRTI)+F/TDF regimens. The E/C/F/TDF appeared to have sustained efficacy and safety and was well tolerated in the small number of ARTnaïve and ART-experienced Asian subjects.
목차
등록된 정보가 없습니다.
참고문헌 (20)
참고문헌 신청
Department for Health and Human Services / Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents
European AIDS Clinical Society / EACS Guidelines Version 8.0
Sax PE / 2012 / Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection:a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks / Lancet 379:2439~2448
DeJesus E / 2012 / Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial / Lancet 379:2429~2438
Zolopa A / 2013 / A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection:analysis of week 96 results / J Acquir Immune Defic Syndr 63:96~100
European AIDS Clinical Society / EACS Guidelines Version 8.0
Sax PE / 2012 / Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection:a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks / Lancet 379:2439~2448
DeJesus E / 2012 / Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial / Lancet 379:2429~2438
Zolopa A / 2013 / A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection:analysis of week 96 results / J Acquir Immune Defic Syndr 63:96~100
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/ Emtricitabine-containing HAART Regimens
Infection and Chemotherapy
2015 .01
-
Tenofovir-induced renal tubular dysfunction among human immunodeficiency virus patients on antiretroviral therapy in Nigeria: Prospects for early detection of presymptomatic nephrotoxicity
Kidney Research and Clinical Practice
2018 .01
-
Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: Two cases
Clinical and Molecular Hepatology
2016 .01
-
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
Clinical and Molecular Hepatology
2016 .01
-
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
Clinical and Molecular Hepatology
2017 .01
-
Management of Antiviral Resistance in Chronic Hepatitis B
Gut and Liver
2017 .01
-
A severe case of tenofovir-associated acute kidney injury requiring hemodialysis in a patient with chronic hepatitis B
Kidney Research and Clinical Practice
2020 .01
-
Incidence and Risk Factors of Tenofovir Disoproxil Fumarate Induced Nephrotoxicity and Renal Function Recovery, a Hospital Case-Control Study
Infection and Chemotherapy
2023 .06
-
The efficacy of Tenofovir-based therapy in patients showing suboptimal response to Entecavir-Adefovr combination therapy
Clinical and Molecular Hepatology
2016 .01
-
Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate
Gut and Liver
2019 .01
-
Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea
Journal of Korean Medical Science
2021 .01
-
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
Clinical and Molecular Hepatology
2024 .04
-
Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
Gut and Liver
2017 .01
-
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
Clinical and Molecular Hepatology
2021 .01
-
Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization
Journal of Liver Cancer
2019 .01
-
Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens
Infection and Chemotherapy
2022 .09
-
Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)idenaïve patients
Clinical and Molecular Hepatology
2017 .01
-
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
Clinical and Molecular Hepatology
2015 .01
-
Effectiveness and Tolerability of Dual Therapy with Dolutegravir Plus Darunavir/cobicistat in Treatment-Experienced Patients with HIV: A 144-Week Follow-Up
Infection and Chemotherapy
2024 .06
-
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Clinical and Molecular Hepatology
2024 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0